Orgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across California
March 16, 2023 07:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 16, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Inc. Announces Closing of $3.7 Million Registered Direct Offering
February 27, 2023 11:46 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Orgenesis, Inc. (Nasdaq: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Inc. Announces Pricing of $3.7 Million Registered Direct Offering
February 23, 2023 09:55 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Orgenesis, Inc. (Nasdaq: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis and Kurve Therapeutics Announce Pre-Clinical Study Results for a Cell-Based Oncolytic Virus Bearing Product Demonstrating Over 50% Reduction in a Murine Glioblastoma Model
December 20, 2022 08:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022
November 10, 2022 16:30 ET
|
Orgenesis Inc.
Secures up to $50 Million of Funding from Metalmark Capital Partners Expected to Accelerate Rollout of Point-of-Care Services Reduces operating expenses by 49% to achieve nearly breakeven income from...
Orgenesis Schedules Third Quarter 2022 Business Update Conference Call
November 10, 2022 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services
November 07, 2022 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Achieves Revenue of $7.2 Million for the Second Quarter of 2022
August 16, 2022 10:23 ET
|
Orgenesis Inc.
Secures Funding from Metalmark Capital Partners to Drive Growth Orgenesis to Host Conference Call Today, August 16, 2022 at 11 AM Eastern Time GERMANTOWN, Md., Aug. 16, 2022 (GLOBE NEWSWIRE) --...
Orgenesis Schedules Second Quarter 2022 Business Update Conference Call
August 15, 2022 09:14 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Achieves Revenue of $7.2 Million for the First Quarter of 2022
May 24, 2022 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...